دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Barriers to Deceased Donor Procurements: The Saudi Experience.
Shaheen, Mohammed F. MSc, MME, MD 1,2,3; Alghafees, Mohammad A. MBBS 1; Alzeer, Zaid A. MBBS 1; Altheaby, Abdulrahman MD 2,3; Shaheen, Faissal A.M. MD 4
doi : 10.1097/TP.0000000000004507
Volume 107(7) pgs. 1407-1641,e188-e189 July 2023
Targeting Cellular Senescence in Organ Transplantation.
Zhou, Hao MD, PhD 1; Tullius, Stefan G. MD, PhD 1
There Is a Lot More to Transplantation Surgery Than the Surgery Itself: The "Other" Sir Peter John Morris, AC, FRS.
Allen, Richard D.M. MBBS, FRACS 1
International Liver Transplantation Society/Society for Advancement of Transplant Anesthesia Consensus Statement on Essential Attributes of a Liver Transplant Anesthesiologist.
Nguyen-Buckley, Christine MD 1; Bezinover, Dmitri S. MD 2; Bhangui, Pooja MD 3; Biancofiore, Gianni MD 4; Blasi, Annabel MD 5; Chadha, Ryan MD 6; Pustavoitau, Aliaksei MD, MHS 7; Sabate, Antoni MD, PhD 8; Saner, Fuat H. MD 9; Wagener, Gebhard MD 10; Wray, Christopher L. MD 1; Zerillo, Jeron MD 11; Pan, Terry Ling Te MBBS 12
doi : 10.1097/TP.0000000000004583
We sought to establish consensus on the essential skills, knowledge, and attributes that a liver transplant (LT) anesthesiologist should possess in a bid to help guide the further training process.
Comments on: Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Lerut, Jan MD, PhD 1; Lai, Quirino MD, PhD 2
Prioritizing the Sickest Among the Sickest: A Matter of Tact and Moderation, but the Game Is Worth the Candle.
Lescroart, Mickael MD 1; Coutance, Guillaume MD, PhD 1,2
Baby Steps Taken in Developing an Understanding of the Long-term Health Consequences of Pregnancy Complications in Living Kidney Donors.
Wyld, Melanie L.R. B.Economics (Hons), MBBS, MBA, MPH, PhD 1,2
Expanding Donor Options for Lung Transplant: Extended Criteria, Donation After Circulatory Death, ABO Incompatibility, and Evolution of Ex Vivo Lung Perfusion.
Noda, Kentaro PhD 1; Furukawa, Masashi MD, PhD 1; Chan, Ernest G. MD, MPH 1; Sanchez, Pablo G. MD, PhD 1
doi : 10.1097/TP.0000000000004480
AB Only using brain-dead donors with standard criteria, the existing donor shortage has never improved in lung transplantation. Currently, clinical efforts have sought the means to use cohorts of untapped donors, such as extended criteria donors, donation after circulatory death, and donors that are ABO blood group incompatible, and establish the evidence for their potential contribution to the lung transplant needs.
Immune Checkpoint Inhibitors in Solid Organ Transplant Recipients With Advanced Skin Cancers-Emerging Strategies for Clinical Management.
Ferrandiz-Pulido, Carla MD, PhD 1; Leiter, Ulrike MD 2; Harwood, Catherine MD, PhD 3; Proby, Charlotte M. MD, FRCP 4; Guthoff, Martina MD 5; Scheel, Christina H. MD 6; Westhoff, Timm H. MD 7; Bouwes Bavinck, Jan Nico MD, PhD 8; Meyer, Thomas PhD 6; Nageli, Mirjam C. MD 9; del Marmol, Veronique MD, PhD 10; Lebbe, Celeste MD, PhD 11; Geusau, Alexandra MD 12
doi : 10.1097/TP.0000000000004459
AB Use of immune checkpoint inhibitors (ICIs) in solid organ transplant recipients (SOTRs) with advanced skin cancers presents a significant clinical management dilemma.
The Utility of Spatial Transcriptomics for Solid Organ Transplantation.
Li, Jennifer S.Y. MBBS, FRACP 1,2; Raghubar, Arti M. MMolBiol 3,4,5,6,7; Matigian, Nicholas A. MPhil 8; Ng, Monica S.Y. MBBS, PhD 3,4,6,7,9; Rogers, Natasha M. MBBS, FRACP, PhD 1,2,10; Mallett, Andrew J. MBBS, FRACP, PhD 6,7,11,12
doi : 10.1097/TP.0000000000004466
AB Spatial transcriptomics (ST) measures and maps transcripts within intact tissue sections, allowing the visualization of gene activity within the spatial organization of complex biological systems. This review outlines advances in genomic sequencing technologies focusing on in situ sequencing-based ST, including applications in transplant and relevant nontransplant settings.
CD40-CD40L Blockade: Update on Novel Investigational Therapeutics for Transplantation.
Singh, Avneesh K. PhD 1; Goerlich, Corbin E. MD, PhD 1; Zhang, Tianshu MD 1; Lewis, Billeta G.T. MS 1; Hershfeld, Alena MS 1; Mohiuddin, Muhammad M. MD 1
doi : 10.1097/TP.0000000000004469
AB Effective immune responses require antigen presentation by major histocompatibility complexes with cognate T-cell receptor and antigen-independent costimulatory signaling for T-cell activation, proliferation, and differentiation.
Caregiver Burden in Adult Solid Organ Transplantation.
Deng, Lisa X. MD 1; Sharma, Arjun MA 1; Gedallovich, Seren M. MD 2; Tandon, Puneeta MD 3; Hansen, Lissi PhD, RN 4; Lai, Jennifer C. MD, MBA 1
doi : 10.1097/TP.0000000000004477
AB The informal caregiver plays a critical role in supporting patients with various end-stage diseases throughout the solid organ transplantation journey.
Therapeutic Effects of Anti-PD1 Immunotherapy on Hepatocellular Carcinoma Under Administration of Tacrolimus.
Hsu, Yu-Chen PhD 1; Chen, Chien-Hung MD, PhD 2,3,4; Huang, Hui-Fu MD 5; Lee, Ying-Te BS 1; Wu, Meng-Chuan PhD 1; Su, Chien-Wen MS 1; Chou, Huei-Chi PD 1; Wang, Li-Fang MD, PhD 1; Lee, Hsuan-Shu MD, PhD 1,3; Lin, Shu-Wha PhD 6,7; Hsu, Ping-Ning MD, PhD 8; Wu, Yao-Ming MD, PhD 5,9; Sheu, Jin-Chuan MD, PhD 1,3; Weng, Meng-Tzu MD, PhD 3,10
doi : 10.1097/TP.0000000000004425
Liver transplantation (LT) is the treatment of choice for patients with hepatocellular carcinoma (HCC). Recurrence of HCC after LT occurs in 10% to 20% of cases.
Subset-specific Retention of Donor Myeloid Cells After Major Histocompatibility Complex-matched and Mismatched Liver Transplantation.
Dart, Sarah J. MSc 1; Prosser, Amy C. BSc 1; Huang, Wen Hua MD 1,2; Liu, Liu 1; Lucas, Andrew D. PhD 3; Delriviere, Luc MD 1,2; Gaudieri, Silvana PhD 4; Jeffrey, Gary P. MD 1,2,5; Lucas, Michaela MD 1,6
doi : 10.1097/TP.0000000000004481
During solid organ transplantation, donor leukocytes, including myeloid cells, are transferred within the organ to the recipient. Both tolerogenic and alloreactive roles have been attributed to donor myeloid cells; however, their subset-specific retention posttransplantation has not been investigated in detail.
Modern Outcomes After Liver Retransplantation: A Single-center Experience.
Connor, Ashton A. MD, PhD 1,2; Saharia, Ashish MD 1,2,3; Mobley, Constance M. MD, PhD 1,2,3; Hobeika, Mark J. MD 1,2,3; Victor, David W. III MD 1,2,3; Kodali, Sudha MD 1,2,3; Brombosz, Elizabeth W. PhD 1; Graviss, Edward A. PhD 1,4; Nguyen, Duc T. MD, PhD 4; Moore, Linda W. PhD 1,3; Gaber, A. Osama MD 1,2,3; Ghobrial, R. Mark MD, PhD 1,2,3
doi : 10.1097/TP.0000000000004500
The need for liver retransplantation (reLT) has increased proportionally with greater numbers of liver transplants (LTs) performed, use of marginal donors, degree of recipient preoperative liver dysfunction, and longer survival after LT.
Induction Immunosuppression Does Not Worsen Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Durkin, Claire MD 1; Schaubel, Douglas E. PhD 2; Xu, Yuwen MS 2; Mahmud, Nadim MD, MS, MPH, MSCE 1,2,3; Kaplan, David E. MD, MS 1,3; Abt, Peter L. MD 4; Bittermann, Therese MD, MSCE 1,2
doi : 10.1097/TP.0000000000004487
Prior studies are inconsistent regarding the impact of antibody induction therapy on outcomes after liver transplantation (LT) for hepatocellular carcinoma (HCC).
Late-onset Chronic Kidney Disease Over 2 Decades After Pediatric Liver Transplantation: A Single-center, Retrospective Study.
Umemura, Kentaro MD 1; Mita, Atsuyoshi MD, PhD 1; Ohno, Yasunari MD, PhD 1; Masuda, Yuichi MD, PhD 1; Yoshizawa, Kazuki MD 1; Kubota, Koji MD, PhD 1; Notake, Tsuyoshi MD, PhD 1; Hosoda, Kiyotaka MD 1; Kamachi, Atsushi MD 1; Goto, Takamune MD 1; Tomida, Hidenori MD 1; Yamazaki, Shiori MD 1; Shimizu, Akira MD, PhD 1; Soejima, Yuji MD, PhD 1
doi : 10.1097/TP.0000000000004465
Although chronic kidney disease (CKD) after liver transplantation (LTx) is a common complication in adults, its long-term significance after pediatric LTx remains unclear
Physical Performance Decline During the Early Posttransplantation Period Affects Survival After Living Donor Liver Transplantation.
Kim, Deok-Gie MD 1; Hwang, Shin MD, PhD 2; Lee, Kwang-Woong MD, PhD 3; Choi, Gyu-seong MD, PhD 4; You, Young Kyoung MD, PhD 5; Ryu, Je Ho MD, PhD 6; Kim, Bong-Wan MD, PhD 7; Nah, Yang Won MD, PhD 8; Kim, Dong-Sik MD, PhD 9; Cho, Jai Young MD, PhD 10; Kang, Koo Jeong MD, PhD 11; Hong, Geun MD, PhD 12; Yu, Hee Chul MD, PhD 13; Ju, Man ki MD, PhD 14; Suh, Suk-Won MD, PhD 15; Kim, Kwan Woo MD, PhD 16; Choi, Dongho MD, PhD 17; Jeong, Jaehong MD, PhD 18; Choi, Soo Jin Na MD, PhD 19; Moon, Ju Ik MD, PhD 20; Lee, Jae Geun MD 1; Kim, Myoung soo MD, PhD 1; Choi, Donglak MD, PhD 21; Joo, Dong Jin MD, PhD 1; and the Korean Organ Transplantation Registry Study Group
doi : 10.1097/TP.0000000000004517
Patient physical performance has been emphasized in liver transplant recipients; however, evidence for living donor liver transplantation (LDLT) patients is lacking.
Optimal Donor Allograft Function: The Search for the Lowest Acceptable Donor Left Ventricular Ejection Fraction in Pediatric Heart Transplantation.
Masotti, Elizabeth S. MD 1; Morrison, John M. MD, PhD 2,3; Fierstein, Jamie L. PhD 4; Ashfaq, Awais MD 5; Carapellucci, Jennifer BSN 5; Khalaf, Racha MD 2,6; Laks, Jessica A. MD 5; Miller, Alexandra MPH 4; Amankwah, Ernest K. PhD 2,4,7; Asante-Korang, Alfred MD 5
doi : 10.1097/TP.0000000000004525
The availability of heart donors is limited by organ shortage. Due to concerns of reduced survival, donors with depressed left ventricular ejection fraction (LVEF <50%) have been cautiously used in pediatric heart transplantation.
The Outcome of Transplanting Kidneys From Very Small Pediatric Deceased Donors.
Zhang, Qiang MD 1; Su, Xiaojun MD 1; Liu, Longshan MD 1; Huang, Mingchuan MD 1; Wu, Wenrui MD 1; Zhang, Huanxi MD 1; Wu, Chenglin MD 1; Fu, Qian MD 1; Gao, Pengfei MD 1; Ling, Liuting BMS 1; Chen, Wenting BS 1; Xu, Bowen BMS 1; Liao, Yuan MPH 1; Li, Jun MD 1; Wang, Changxi MD, PhD 1,2,3
doi : 10.1097/TP.0000000000004534
Kidneys from very small pediatric donors (VSPDs, aged <2 y) are underutilized. Concerns regarding potentially inferior outcomes hinder the use in pediatric recipients.
Intraoperative Red Blood Cell Transfusion and Primary Graft Dysfunction After Lung Transplantation.
Subramaniam, Kathirvel MD, MPH, FASE 1; Loor, Gabriel MD 2; Chan, Ernest G. MD, MPH 3; Bottiger, Brandi A. MD 4; Ius, Fabio MD 5; Hartwig, Matthew G. MD 6; Daoud, Daoud MD 7; Zhang, Qianzi MPH 8; Wei, Qi MD, MS 9; Villavicencio-Theoduloz, Mauricio A. MD 10; Osho, Asishana A. MD 11; Chandrashekaran, Satish MD 12; Noguchi Machuca, Tiago MD, PhD 13; Van Raemdonck, Dirk MD, PhD 14; Neyrinck, Arne MD, PhD 15; Toyoda, Yoshiya MD, PhD 16; Kashem, Mohammed A. MD 16; Huddleston, Stephen MD, PhD 17; Ryssel, Naomi R. MPH 3; Sanchez, Pablo G. MD, PhD 3
doi : 10.1097/TP.0000000000004545
In this international, multicenter study of patients undergoing lung transplantation (LT), we explored the association between the amount of intraoperative packed red blood cell (PRBC) transfusion and occurrence of primary graft dysfunction (PGD) and associated outcomes. Methods.
Natural Antibodies Are Associated With Rejection and Long-term Renal Allograft Loss in a Multicenter International Cohort.
See, Sarah B. PhD 1; Yang, Xue MSc 2; Burger, Carole MD 3; Lamarthee, Baptiste BSc 4; Snanoudj, Renaud MD 5; Shihab, Ronzon BSc 1; Tsapepas, Demetra S. PharmD 6; Roy, Poulomi BSc 1; Lariviere-Beaudoin, Stephanie BSc 7,8; Hamelin, Katia MSc 7; Mendoza Rojas, Aleixandra PhD 9; van Besouw, Nicole M. PhD 9; Bartosic, Amanda MBA 10; Daniel, Nikita BSc 10; Rodica, Vasilescu E. MD 11; Mohan, Sumit MD 12,13; Cohen, David MD 12; Ratner, Lloyd MD 12; Baan, Carla C. MD 9; Bromberg, Jonathan S. MD 10; Cardinal, Heloise MD 7,8; Anglicheau, Dany MD 3; Sun, Yifei PhD 2; Zorn, Emmanuel PhD 1
doi : 10.1097/TP.0000000000004472
Potentially harmful nonhuman leukocyte antigen antibodies have been identified in renal transplantation, including natural immunoglobulin G antibodies (Nabs) reactive to varied antigenic structures, including apoptotic cells.
Cardiovascular Outcomes in De Novo Kidney Transplant Recipients Receiving Everolimus and Reduced Calcineurin Inhibitor or Standard Triple Therapy: 24-month Post Hoc Analysis From TRANSFORM Study.
Sommerer, Claudia MD 1; Legendre, Christophe MD 2; Citterio, Franco MD, FEBS 3; Watarai, Yoshihiko MD, PhD 4; Oberbauer, Rainer MD 5; Basic-Jukic, Nikolina MD, PhD 6; Han, Jackie MSc 7; Gawai, Apurva MD 8; Bernhardt, Peter PhD 9; Chadban, Steve MD, PhD 10
doi : 10.1097/TP.0000000000004555
The comparative impact of everolimus (EVR)-based regimens versus standard of care (mycophenolic acid+standard calcineurin inhibitor [MPA+sCNI]) on cardiovascular outcomes in de novo kidney transplant recipients (KTRs) is poorly understood.
Temporary Mechanical Circulatory Support Use and Clinical Outcomes of Simultaneous Heart/Kidney Transplant Recipients in the Pre- and Post-heart Allocation Policy Change Eras.
Agdamag, Arianne C. MD 1; Riad, Samy MD 2; Maharaj, Valmiki MD 1; Jackson, Scott MS 3; Fraser, Meg DNP, NP-C 1; Charpentier, Victoria BS 4; Nzemenoh, Bellony MD 5; Martin, Cindy M. MD 1; Alexy, Tamas MD, PhD 1
doi : 10.1097/TP.0000000000004518
The use of temporary mechanical circulatory support (tMCS) devices (intra-aortic balloon pump; Impella 2.5, CP, 5.0; venoarterial extracorporeal membrane oxygenation) increased significantly across the United States for heart transplant candidates after the allocation policy change.
Long-term Outcomes Associated With Post-kidney Donation Pregnancy Complications.
Palzer, Elise F. MS 1; Helgeson, Erika S. PhD 1; Evans, Michael D. MS 2; Vock, David M. PhD 1; Matas, Arthur J. MD 3
doi : 10.1097/TP.0000000000004540
Kidney donors have increased risk of postdonation gestational hypertension (gHTN) and preeclampsia. In the general population, pregnancy complications are associated with long-term maternal risk.
Primary Graft Dysfunction Is Associated With Development of Early Cardiac Allograft Vasculopathy, but Not Other Immune-mediated Complications, After Heart Transplantation.
Han, Jiho MD, MS 1; Moayedi, Yasbanoo MD 2; Henricksen, Erik J. PharmD 3; Waddell, Kian BA 4,5; Valverde-Twiggs, Julien BS 5; Kim, Daniel BS 5; Luikart, Helen RN 5; Zhang, Bing M. MD, MS 6; Teuteberg, Jeffrey MD 5; Khush, Kiran K. MD, MAS 5
doi : 10.1097/TP.0000000000004551
We investigated associations between primary graft dysfunction (PGD) and development of acute cellular rejection (ACR), de novo donor-specific antibodies (DSAs), and cardiac allograft vasculopathy (CAV) after heart transplantation (HT).
Multicenter Validation of a Urine CXCL10 Assay for Noninvasive Monitoring of Renal Transplants.
Ho, Julie MD 1,2; Schaub, Stefan MD, MSc 3,4,5; Jackson, Annette M. PhD 6; Balshaw, Robert PhD 7; Carroll, Robert MD, PhD 8; Cun, Sylvia BSc 9; De Serres, Sacha A. MD, MSc 10; Fantus, Daniel MD 11; Handschin, Joelle MSc 3; Honger, Gideon PhD 3,4,5; Jevnikar, Anthony M. MD 12; Kleiser, Marc BSc 5; Lee, Jar-How PhD 13; Li, Yan PhD 6; Nickerson, Peter MD 1,2,14; Pei, Rui PhD 9; Pochinco, Denise MLT 14; Shih, Remi PhD 13; Trinh, Michael PhD 9; Wang, Jason BSc 9; Nguyen, Julie PhD 9; Knechtle, Stuart MD 6
doi : 10.1097/TP.0000000000004554
Urine CXCL10 (C-X-C motif chemokine ligand 10, interferon gamma-induced protein 10 [IP10]) outperforms standard-of-care monitoring for detecting subclinical and early clinical T-cell-mediated rejection (TCMR) and may advance TCMR therapy development through biomarker-enriched trials.
Humoral Response After Five Successive Doses of SARS-CoV-2 mRNA Vaccine in Kidney Transplant Patients.
Cazorla, Juan Manuel MD 1; Villanego, Florentino 1; Aguilera, Aurora 1; Garcia, Teresa 1; Orellana, Cristhian 1; Trujillo, Teresa 2; Gomez, Ana Maria 1; Mazuecos, Auxiliadora 1
